Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nab-paclitaxel vs docetaxel with oxaliplatin and S-1 in locally advanced gastric cancer
ChiCTR2100048252Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric cancer (GC) comparing nab-paclitaxel + oxaliplatin + S-1 with docetaxel + oxaliplatin + S-1 (2 arms). Primary endpoint: tumor regression grade. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
paclitaxeldocetaxeloxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100048252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048252.